A Study of Stem Cells and Filgrastim

Inclusion Criteria Concurrent Medication: Allowed: * PCP prophylaxis. * Antiretroviral therapy in patients with CD4 counts \<= 500 cells/mm3. * Narcotic analgesics for grade 3/4 bone pain toxicity. Patients must have: * HIV infection. * HIV infected patients with CD4 count \> 500 cells/mm3 must be asymptomatic. Patients with CD4 count 200-500 cells/mm3 may be either asymptomatic or symptomatic but must not have AIDS. Patients with CD4 count \< 200 cells/mm3 may or may not have AIDS-defining conditions. * No antiretroviral therapy within the past 30 days in patients with asymptomatic disease and CD4 count \> 500 cells/mm3. * Stable antiretroviral therapy for the past 60 days if CD4 count \<= 500 cells/mm3. * Suitable venous access. Prior Medication: Allowed: * Prior antiretroviral therapy. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Current malignancy. * Any medication condition that interferes with study evaluation. * Known hypersensitivity to E. coli-derived proteins (e.g., insulin, human growth hormones). Concurrent Medication: Excluded: * Acute treatment for serious opportunistic infection. * Systemic cytotoxic chemotherapy. Concurrent Treatment: Excluded: * Systemic radiation therapy. Patients with the following prior conditions are excluded: * Prior malignancy. * Leukapheresis or lymphopheresis within the past 180 days. * Significant active CNS disease or seizures within the past year. Prior Medication: Excluded: * G-CSF or GM-CSF within the past 6 months. * Investigational antiretrovirals within the past 30 days. * Treatment for opportunistic infection within the past 14 days. Active alcohol or substance abuse.